Publiziert in: Marktpuls, Unternehmen
Frei

Ypsomed opens new production hall in Schwerin and announces further expansion Donnerstag, 17. Oktober 2024 - 07:12

LOG_Ypsomed.png

Media release

Ypsomed opens new production hall in Schwerin and announces further expansion 

Burgdorf, 17.10.2024, 7 a.m. – Today Ypsomed celebrates the opening of a new production hall at its German site in Schwerin. The expansion will enable the company to increase its production capacity to meet the growing global demand for high-quality medical technology products. CEO of Ypsomed, Simon Michel, also announced a further expansion of the plant in the coming years. 

Newsletter-YPS_BUI_Schwerin_02.jpg

A total of 22 million CHF was invested in the new production hall D. It is an extension of the existing site with halls A-C, with a production area of 3,400 square metres and is equipped with the latest building technology. With 30 state-of-the-art plastic injection moulding machines and three assembly lines, Ypsomed will be able to produce an additional 100 million autoinjectors per year in Schwerin. "The expansion of our Schwerin site is an important step in our growth strategy, which will enable us to increase our production capacity and expand further in the coming years," says Simon Michel, CEO of Ypsomed AG.  

Investing in the future: expansion in Schwerin  

After more than two years of planning, the construction of Schwerin II will begin in January 2025. In the first phase, which is expected to take almost two years, the production area will be expanded by 25,000 square metres. In the second construction phase, which is expected to begin in 2027/28, a further 17,000 square metres of production space will be added. This will increase the Ypsomed Group's production capacity by 400 to 500 million pens and autoinjectors per year. The planned investment sum amounts to almost half a billion Swiss francs. 

Sustainable construction and future-oriented energy supply 

In addition to technological innovation, Ypsomed also relies on sustainable production methods. The roofing of the production buildings at the Schwerin site are completely equipped with photovoltaic systems to cover as much of the energy requirement as possible with solar energy. It is also planned to install a wind turbine to generate its own electricity and to use rainwater to minimise the environmental impact of the site. In addition, Ypsomed will offset the remaining, unavoidable 2,200 tonnes of CO2 equivalent from Hall D with certificates. This makes Hall D a "CO2-neutral building". 

Creating new jobs and apprenticeships 

With the newly opened production hall, Ypsomed is initially creating 85 additional jobs and new apprenticeships in Schwerin. The first phase of the Schwerin II project will create around 350 new jobs. Ypsomed is not only expanding its production capacity but is also making an important contribution to the economic development of the region and offering young people in Mecklenburg-Vorpommern long-term career prospects. 

Contact

Susanne Kühler, Head of Public Relations, Ypsomed Holding AG
+41 34 424 47 32, susanne.koehler@ypsomed.com

This communication and the media material can be found at www.ypsomed.com/pressreleases

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. The company will celebrate its 40th anniversary in 2024. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. Ypsomed is headquartered in Burgdorf, Switzerland. The company has a global network of production facilities, subsidiaries, and distribution partners with around 2,600 employees worldwide.
www.ypsomed.com

Ypsomed AG, Brunnmattstrasse 6, 3401 Burgdorf
info@ypsomed.com, www.ypsomed.com